Days before the Jets’ ESPN documentary premiered, former defensive end Mark Gastineau’s feud with Brett Favre made waves on social media on Tuesday. At a Chicago sports memorabilia show last year as part of ESPN’s 30 for 30 documentary about “The New York Sack Exchange,” which premieres Friday at 8 p.m. ET, Gastineau confronted Favre and accused him of letting Giants defensive end Michael Strahan sack him to break his record in 2001. “I was there during that moment, and it was unexpected,” director Ken Rodgers told the Daily News about Gastineau confronting Favre. “We were just following Mark around a card show and if he’s anything, he is still passionate. “You saw it on the football field as a sack master celebrating and he is still as passionate about what he feels and believes. In retrospect, maybe I’m not as surprised that he would have that moment with Favre now that we’ve experience so much time with him and done interviews with him and seen his career. “At the time, it was totally unexpected that happened.” During the interaction in Chicago, Favre and Gastineau shook hands, and Favre mentioned to the former defensive end how they had met before. “Yeah, right — when you fell down for [Strahan],” said Gastineau. “I’m going to get my sack back. I’m going to get my sack back, dude.” A surprised Favre replied, “You probably would hurt me,” and Gastineau shouted back, “Well, I don’t care. You hurt me. You hurt me! You hear me?” “Yeah, I hear you,” Favre replied. “You really hurt me. You really hurt me, Brett,” Gastineau said to Favre before a handler escorted him away. Gastineau is clearly still angry about the final game of the 2002 season between the Packers and Giants when Strahan broke his controversial single-season sack record (22). Many believe Favre fell on purpose to give Strahan the record of 22.5. At the time, Gastineau attended the game and hugged Strahan afterward. However, he later expressed his feelings about Strahan breaking the record in an ESPN interview in 2020 . During the documentary, Gastineau said about the incident, “Anybody will tell you that Brett Favre took a dive.” Steelers pass rusher T.J. Watt equaled Strahan’s record of 22.5 in 2021. Favre addressed the incident between him and Gastineau on X in a long thread . The three-time NFL MVP said he didn’t intentionally take the sack to hurt Gastineau. “There was no malice on my part,” Favre said in the post. He also endorsed Gastineau for the Pro Football Hall of Fame. “He was made to be an enemy by the media, which we can see in that Phyllis George interview,” James Weiner, who also directed the documentary, told the Daily News about Gastineau. “They blame him for the [sack dance] rule change. He feels like the world has been against him, rightly or wrongly and he got some good points. “The Favre-Strahan sack record, there are a lot of people who think that the league wanted Strahan to have the sack record. He was a popular player among a lot of people, the league, and opponents, and Gastineau was not a popular player. So, you had two popular players involved in this controversial incident and Gastineau was perceived as the bad guy back then, so there wasn’t much sympathy for him. “Twenty-three years later, we look at it a little bit differently perhaps.” “The New York Sack Exchange” 30 for 30 examines the rise and fall of the Jets’ defensive line from the late 1970s through the 1980s. It also details the relationships between Gastineau, teammates Joe Klecko, Marty Lyons, and the late Abdul Salaam, who died in October . “I’m sorry, he won’t get to see the finished film,” Weiner said about Salaam. “But I’m happy he was a big part of it. I keep telling Ken, the timing of this thing was unbelievable.” The documentary is narrated by musician, actor, and lifelong Jets fan Method Man, and the film is directed by Rodgers (The Tuck Rule, The Two Bills, Four Falls of Buffalo) and Weiner (The Brady 6, SEC Storied: Saturday Night Lights,), who grew up in Long Island in Port Washington. Rodgers wants people to take away a special message when watching the documentary. “For me, it’s never too late to forgive past transgressions between people,” he said. “It’s really hard to get along with people you work with because you’re all striving towards different individual goals at the same time. Not everybody that works together gets along, let alone out in the real world or at the supermarket. “These guys disliked each other on some level more than most people dislike their coworkers. It was real, the anger and frustration, so much so, they’re still working through it, but they are still working through it. “I’m sitting at a reunion with somebody 30 years from now, I’m not going to care about those little transgressions that make me upset. The impact the film had on me was to reevaluate my work relationships and realize that if these guys can sit down and talk with each other and work things out, then anybody can.”Gilstrap’s “Six Minutes to Freedom” to go to the big screenNoneSouth Carolina looks to steady ship against South Carolina Upstatebest online casino sites real money 。

Cavalier boys drop 72-64 game to PurdySAN FRANCISCO , Dec. 26, 2024 /PRNewswire/ -- AusperBio Therapeutics, Inc . and Ausper Biopharma Co., Ltd . (collectively AusperBio ), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B ( CHB ), today announced the successful completion of a USD 73 million Series B financing. The round was led by HanKang Capital , with participation from Sherpa Capital , CDH Investments , and a strategic investor, as well as continued participation from existing investors Qiming Venture Partners , InnoPinnacle Fund , and YuanBio Venture Capital . This financing followed the company's Series A round completed in July this year, demonstrating continued investor confidence in its proprietary platform and strategic direction. The proceeds will fund the continued Phase 2 development of AHB-137 , AusperBio's lead investigational therapy, supporting both clinical studies in China and global trials, as well as the development of commercial-scale manufacturing processes. The funding will also facilitate the expansion of the company's therapeutic pipeline and operational capabilities to drive sustained growth. Dr. Guofeng Cheng , co-founder and CEO of AusperBio, stated, " We are honored by our investors' confidence and support. This milestone financing recognizes our scientific and clinical accomplishments to date and enables us to accelerate our clinical programs and move closer to delivering a functional cure for CHB patients in need." Dr. Chris Yang , co-founder and CSO, added, "AHB-137 continues to attract attention from the scientific and clinical communities, particularly after the late-breaking oral presentation at the recent AASLD conference. The promising clinical data further validates our Med-OligoTM platform, strengthening our development of groundbreaking targeted oligonucleotide therapies for CHB and other serious chronic diseases." AusperBio is committed to delivering patient-centered innovations, aiming to alleviate the global health burden of CHB and transform treatment paradigms for this serious chronic disease. About AHB-137 AHB-137, a novel unconjugated antisense oligonucleotide ( ASO ) developed within AusperBio's proprietary Med-OligoTM ASO technology platform, was designed to treat chronic hepatitis B for a functional cure. Its compelling preclinical and Phase 1 clinical data were highlighted at the 2023 EASL conference and the 2024 EASL conference, respectively. Interim Phase 2a data was presented in a late-breaking oral session at the 2024 AASLD. This novel dual-mechanism ASO has completed its global Phase 1b trial and is now undergoing multiple Phase 2 trials in China . With its global development strategy, AHB-137 is advancing rapidly toward the goal of an HBV cure. About AusperBio. AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China , dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B infection. The company has developed a proprietary Med-OligoTM ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligoTM Platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. For further information, please contact: Media Contact Email: info@ausperbio.com Investor Relations Contact: Tel: 650-888-1756 (US) Email: growth@ausperbio.com View original content to download multimedia: https://www.prnewswire.com/news-releases/ausperbio-secures-73-million-in-series-b-financing-to-advance-functional-cure-for-chronic-hepatitis-b-302339451.html SOURCE AusperBio Therapeutics Inc.

Conners, Tate lead Appalachian State over Sam Houston 66-63Transplant recipients show better physical, school, and social functioning than those receiving transfusions and medications alone LBA-5: Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities SAN DIEGO, Dec. 10, 2024 /PRNewswire/ -- Children who received a stem cell transplant for sickle cell disease (SCD) experienced better quality of life outcomes and cognitive performance 10 years after their transplant compared with children who received chronic transfusion therapy and the SCD drug hydroxyurea but did not undergo a stem cell transplant. This is according to new study results presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The findings reflect 10-year outcomes from the DREPAGREFFE-1 trial, which ran from 2010-2013 in France, and was the first head-to-head comparison of allogeneic stem cell transplantation versus standard of care for children with SCD. Combined with the study's one-year and three-year outcomes, the 10-year findings further strengthen the evidence in favor of stem cell transplantation for reducing complications and improving the overall outlook for people living with SCD, according to the researchers. "This trial demonstrated that following stem cell transplantation, patients had a better quality of life, not only for physical functioning but also for social and school functioning," said the study's lead author, Françoise Bernaudin, MD, a physician at Hôpital Intercommunal de Créteil, Université Paris-Est, in France. "We found that these patients can have a greater ability to do sports and run, attained higher academic degrees, are not anxious about their future, and experience less anger and less difficulty with memory compared with those who received chronic transfusions and hydroxyurea." SCD is an inherited blood disorder that causes red blood cells to become sickle-shaped, impeding the flow of blood and reducing the ability for blood to carry oxygen to tissues and organs. This results in episodes of acute pain as well as long-term damage, causing a range of complications throughout life and increasing the risk of premature death. One common SCD complication is abnormally high cerebral arterial velocities, an indicator of stenosis presence or reduced oxygen delivery to the brain, which can be associated with a greater risk of strokes and cognitive problems. DREPAGREFFE-1 enrolled 67 children between ages five to 15 who were receiving chronic blood transfusions to prevent complications from abnormal cerebral arterial velocities. Those with a matched sibling donor (n=32) were transplanted while those without a matched sibling donor (n=35) continued their transfusions and then switched to hydroxyurea in absence of stenosis and if their cerebral arterial velocities normalized. At one and three years, those who received a stem cell transplant showed significant improvements in several measures compared with those who did not receive a transplant, but at those timepoints there was no difference in the presence of ischemic lesions (blood clots that block blood flow in the brain) or cognitive performance. In the subsequent years, researchers continued to follow up with study participants, including through clinical evaluations, brain scans, and tools for assessing quality of life and cognitive functioning. At 10 years, quality of life scores related to physical, school, and social functioning were significantly higher among those who received a stem cell transplant. For cognitive performance, participants who received a stem cell transplant showed significantly better performance on tests used to assess working memory and processing speed. There was no difference between groups in terms of verbal comprehension, perceptual reasoning, or emotional quality of life scores. The researchers also assessed trends in the rate of silent cerebral infarcts (SCIs) – a type of small stroke that is visible on a brain scan but causes no obvious symptoms. While it is unclear whether SCIs influence cognitive functioning, they are considered to be a sign of increased SCD severity and complications. SCIs were found in 18 participants at the time of enrollment; at 10 years, five additional patients had developed silent cerebral infarcts in the standard-of-care arm compared to zero in the stem cell transplant arm. Taken together, researchers said that the study findings suggest that undergoing stem cell transplantation results in better outcomes for children with SCD compared with chronic transfusions and hydroxyurea. While this can offer additional reassurance for patients, families, and physicians who are considering the procedure, Dr. Bernaudin noted that families should also be aware of the risks of undergoing a stem cell transplant, including infertility, which is a common side effect of the conditioning regimen used to clear the bone marrow in preparation to receive a transplant. She said that fertility preservation procedures are available in France for all patients undergoing stem cell transplantation for SCD at no charge to the families, adding, "with this technique, we hope that the patients will be able to have children after the transplantation." Looking ahead, Dr. Bernaudin said that it would be useful to compare outcomes from haplo-identical stem cell transplant to gene therapy, a type of treatment that has become more widely available since DREPAGREFFE-1 was conducted. She also noted that additional work is needed to further improve transplantation techniques to minimize the risk of complications or treatment failure particularly after haplo-identical transplants in children. This study was sponsored by the Centre Hospitalier Intercommunal de Créteil (CHIC Hospital) in France and was funded by the Agence de Biomédecine and Pfizer. Françoise Bernaudin, MD, Hôpital Intercommunal de Créteil, Université Paris-Est, will discuss this study in the Late-Breaking Abstracts session on Tuesday, December 10, 2024, at 7:30 a.m. Pacific time in Hall B (San Diego Convention Center). About the American Society of Hematology The American Society of Hematology (ASH) ( hematology.org ) is the world's largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. Since 1958, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The Blood journals ( https://ashpublications.org/journals ) are the premier source for basic, translational, and clinical hematological research. The Blood journals publish more peer-reviewed hematology research than any other academic journals worldwide. View original content to download multimedia: https://www.prnewswire.com/news-releases/undergoing-stem-cell-transplant-for-sickle-cell-disease-in-childhood-improves-quality-of-life-a-decade-later-302327721.html SOURCE American Society of Hematology Copyright © 2024 PR Newswire Association LLC. All Rights Reserved.

Tweet Facebook Mail Woolworths has lodged an application with Fair Work to stop striking workers from blocking access to distribution centres as stock runs low across the country. The grocery giant is seeking orders from the workplace regulator to prevent the United Workers Union (UWU) stopping employees from entering the Melbourne south regional distribution centre and three other sites in Victoria and NSW. The application alleges UWU members are in breach of the good faith bargaining requirements of the Fair Work Act. READ MORE: What the weather on Christmas Day is forecast to be in your city Woolworths shelves are bare and stores are running low on stock as strikes forced the closure of five distribution centres. (Nine) "The application comes after the UWU refused to give any assurance of safe passage for team members seeking to return to work at our Melbourne south regional distribution centre yesterday and this morning," Woolworths said in a statement. "A majority of the team at the site had indicated they wished to return to work to begin being paid, which will help increase supply of essential food and grocery products such as nappies, toilet paper and drinks to Woolworths' Victorian stores." READ MORE: Billionaire brings $150,000 grocery giveaway to Sydney Surprising state where households fork out most for electricity View Gallery Picketers have disrupted the supply chain and resulted in empty shelves in stores. (April Lombardo) Woolworths claims UWU created an "unsafe environment for team members who had shown up to work". "The majority of our team members at this site are not members of the UWU," the statement continued. "We will again be attempting to operate the MSRDC today, and we will follow the advice of the Victorian police to ensure the safety of our team." The application has not been listed for hearing yet. READ MORE: Three dead and dozens sick from eating sea turtle stew UWU logistics coordinator Andrew Giles. (Nine) Union members commenced industrial action at the Woolworths distribution centres to demand better pay and conditions. The strike has now entered its 13th day and as a result supermarket shelves have been left empty ahead of a busy pre-Christmas period. Workers are demanding a pay rise above inflation, seeking an immediate 25 per cent increase and a further 30 per cent over the next two years. They are also wanting the productivity "framework" scrapped, which forces them to meet 100 per cent adherence to a speed-related metric known as pick rates. The strike follows six months of unsuccessful negotiations. DOWNLOAD THE 9NEWS APP : Stay across all the latest in breaking news, sport, politics and the weather via our news app and get notifications sent straight to your smartphone. Available on the Apple App Store and Google Play .